An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
Stopped The study was terminated due to withdrawal of institutional support, Phase II never began.
Conditions
- Hodgkin's Lymphoma
- Mature T-cell Lymphoma
- Multiple Myeloma
Interventions
- DRUG: lenalidomide (Revlimid) and romidepsin (Istodax)
Sponsor
Yale University
Collaborators